Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy
Dal Negro RW, Pradelli L, Tognella S, Micheletto C, Iannazzo S

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details
Dal Negro RW, Pradelli L, Tognella S, Micheletto C, Iannazzo S. Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy. European Annals of Allergy and Clinical Immunology 2011; 43(2): 45-53

PubMedID
21608372

Original Paper URL
http://tinyurl.com/6lfecown

Indexing Status
Subject indexing assigned by NLM

MeSH
Adult; Aged; Anti-Asthmatic Agents /therapeutic use; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal /economics /therapeutic use; Antibodies, Monoclonal, Humanized; Asthma /drug therapy /psychology; Economics, Pharmaceutical; Female; Health Care Costs; Humans; Italy; Male; Middle Aged; Omalizumab; Quality of Life; Quality-Adjusted Life Years

AccessionNumber
22011001516

Date bibliographic record published
05/10/2011